IC
CERE

Ikarian Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Ikarian Capital’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-178,100
Closed -$5.03M – 109
2022
Q3 		$5.03M Buy
+178,100
New +$5.3M 1% 36
2021
Q4 		– Sell
-53,370
Closed -$1.57M – 240
2021
Q3 		$1.57M Buy
+53,370
New +$1.5M 0.11% 137

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ikarian Capital's CERE Position: Q4 2022 in Review

Ikarian Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2022, closing a stake of 178,100 shares — an estimated $5.03M sold.

Ikarian Capital first reported a position in CERE in Q3 2021 and held it in 2 quarters. The position peaked at $5.03M in Q3 2022. 125 funds tracked by Wall St. Rank hold CERE as of Q4 2022.

  • Ikarian Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ikarian Capital sold 178,100 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $5.03M.
  • Ikarian Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Ikarian Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $5.03M in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Ikarian Capital's 13F filing for Q4 2022, filed 14 Feb 2023.